Moxonidin Actavis (Moxonidine)

Moxonidine, the active ingredient in Moxonidin Actavis, is an imidazoline receptor agonist presented as a tablet for oral use. It lowers blood pressure in adults with essential hypertension.

GNH USA supplies Moxonidin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine is used to manage conditions within the hypertension disease family by reducing sympathetic nervous system activity.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Primary hypertension: helps achieve target blood pressure levels when lifestyle measures are insufficient. - High blood pressure: contributes to cardiovascular risk reduction by maintaining controlled blood pressure.

Moxonidine may cause a range of adverse reactions.

Common Side Effects: - Dry mouth: sensation of oral dryness without obvious cause. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headedness, especially when standing quickly. - Headache: mild to moderate pain in the head region.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate that may cause fainting. - Allergic reactions: rash, itching, swelling, or difficulty breathing.

Before prescribing Moxonidin Actavis, clinicians should consider several safety measures. - Monitor blood pressure: check regularly to avoid excessive lowering. - Renal impairment: adjust use in patients with reduced kidney function. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Elderly patients: start at lower dose and watch for dizziness. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Moxonidine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Clonidine: combined central antihypertensive effect may cause profound hypotension. - Other imidazoline agonists: additive sympathetic inhibition. - Potent CYP2D6 inhibitors: may increase plasma levels of moxonidine.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance blood‑pressure‑lowering effect. - ACE inhibitors: potential for additive hypotensive response. - NSAIDs: can blunt antihypertensive efficacy. - Beta‑blockers: monitor for excessive heart‑rate reduction.